Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2022 | $5.00 → $2.00 | Buy | BTIG |
| 12/20/2021 | $8.00 → $2.50 | Buy | Chardan Capital |
| 12/16/2021 | $2.00 | Buy | HC Wainwright & Co. |
| 9/15/2021 | $5.00 | Buy | BTIG |
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) - Watch the "What This Means" video here PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a Virtual Investor "What This Means" segment.As part of the segment, Dr. Richard Kenney, Chief Medical Officer, discussed its recent update on its SB221 clinical trial including that a) enrollment of
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong potential for clinical benefit using the current maximum dose of SON-1010 A second patient with PROC in the E6 combination cohort recently had a confirmed PR, so 2 out of 3 total patients had a tumor response at that dose After completing enrollment of the expansion group at that top dose, a new E7 cohort has been added to examine the safety and effectiveness of a 25% higher maintenance dose of SON-1010 PRINCETON, N.J., Aug. 04, 2025 (GLOBE NEW
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ:SONN) ("Sonnet" or the "Company") today announced that it has entered into a definitive agreement (the "Business Combination Agreement", or the "BCA") for a business combination (the "Business Combination") with Rorschach I LLC ("Rorschach"), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC ("Atlas"), an affiliate of Paradigm Operations LP ("Paradigm"), and additional sponsors (all together, the "Sponsors"), to transform its business by building a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain. At the closing of the Business Combination, the newly-
BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously
Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously
HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00
DEF 14A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa
Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)